Establishment Labs Holdings, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $60.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Josh Jennings has given his Buy rating due to a combination of factors, primarily focusing on the promising data from Establishment Labs Holdings’s Mia Femtech platform. The recent publication in the Aesthetic Surgery Journal highlights the platform’s safety and effectiveness, showing very low complication rates and high satisfaction among both patients and surgeons.
The positive results from the study, including a low reoperation rate and significant patient satisfaction, reinforce the potential of the Mia Femtech platform to support the company’s growth objectives. Jennings also notes that the company’s target of achieving $30M in sales by 2026 for its minimally invasive platform is encouraging, as it demonstrates confidence in the market expansion potential. The ongoing global launch and commercialization strategy for Mia and Preservé further solidify the company’s position in the market, making it a compelling investment opportunity.
Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Medtronic. According to TipRanks, Jennings has an average return of 2.5% and a 47.79% success rate on recommended stocks.
In another report released on October 6, Mizuho Securities also reiterated a Buy rating on the stock with a $70.00 price target.